YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Re…
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the “Notice”)…
Enlivex Therapeutics logo Key Points Enlivex reported $1.23 billion in net income and $25.48 diluted EPS for 2025, ending the year with $2.31 billion in treasury assets and $1.93 billion in shareholders’ equity, results management attribut…
ORLANDO, FL / ACCESS Newswire / February 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Fintech & Digital Ass…
Prediction markets may be booming, but that’s not what’s sent Rain Protocol’s native token soaring 100% over the last 4 hours. On Monday, Enlivex, a Nasdaq-listed biopharma company, said it would acquire $212 million of Rain, the native to…
- Selepas penutupan penempatan persendirian, Enlivex akan mengguna pakai strategi perbendaharaan aset digital token pasaran ramalan RAIN pertama di dunia melalui pengumpulan token RAIN. - RAIN ialah protokol ramalan dan opsyen yang terdese…
- Tras el cierre de la colocación privada, Enlivex adoptará la primera estrategia de tesorería de activos digitales basada en mercados de predicción del mundo, mediante la acumulación del token RAIN. - RAIN es un protocolo totalmente desce…
- Após o fechamento da colocação privada, a Enlivex adotará a primeira estratégia de tesouro de ativos digitais de token de previsão RAIN do mundo, por meio do acúmulo de token RAIN. - RAIN é um protocolo de previsões e opções totalmente d…
- 私募のクロージング後、エンライベックスはRAINトークンの蓄積を通じて、世界初のRAIN予測市場トークンデジタル資産財務戦略を採用する。 - RAINは完全に分散化された予測・オプションプロトコルで、予測市場エコシステムを再定義し、透明性、自動化、コミュニティ参加を基盤としたオンチェーン市場創出のための強力なプラットフォームを提供する。 - イタリア元首相マッテオ・レンツィ氏が、私募のクロージング後、エンライベックス取締役に任命される。 - エンライベックスは、変形性膝…
Enlivex Therapeutics (ENLV), an Israel-based clinical-stage biotech firm, said it’s raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token as its ma…
- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol…
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) on Monday announced a private investment in public equity of 212 million shares at $1.00 per share, representing a premium of 11.5% from the closing price of the stock on November 21, 2025. The compa…
[Hygiene women worker work in science laboratory. people in pharmaceutical medicine production machine inspector.] coffeekai * Enlivex Therapeutics (ENLV [https://seekingalpha.com/symbol/ENLV]) on Monday reported [https://seekingalpha.com/…
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase…
(RTTNews) - Trading after the bell was relatively muted on Thursday, with small-cap biotech names showing modest shifts. Delcath Systems edged higher following its buyback announcement, while BioVie, Cassava Sciences, and Enlivex Therapeut…
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abs…
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflamm…
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX [https://www.…
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT SNGX [https://www.chartmill.com/stock/quo…
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT ASBP…
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function,…
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of i…
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik He…
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative, highly-differentiated modality for immune…
Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the…
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21…
Enlivex Therapeutics Ltd Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improv…
Enlivex Therapeutics Ltd Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient…
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed under the…
Enlivex Therapeutics Ltd Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohor…
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.The…
Enlivex Therapeutics Ltd Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a…
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the…
Enlivex Therapeutics Ltd Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today ann…
Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster prese…
Enlivex Therapeutics Ltd Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a Europe…